Prior Oral Anticoagulant Use in OCEANIC-AF

This secondary analysis of the Oral Factor 11a Inhibitor Asundexian as Novel Antithrombotic–Atrial Fibrillation (OCEANIC-AF) randomized clinical trial investigates if patients with atrial fibrillation and no prior exposure to oral anticoagulants (OACs) may respond differently to a new OAC than patients with a history of OAC exposure.